세계 GLP-1 유사체 시장 규모는 예측 기간인 2025-2032년 23.59%의 연평균 복합 성장률(CAGR)로 2024년 416억 3,000만 달러에서 2032년 2,266억 1,000만 달러로 확대될 것으로 예측됩니다. 2형 당뇨병 및 비만과 같은 만성 대사성 질환의 관리에 있어 GLP-1 수용체 작용제에 대한 의존도가 높아짐에 따라 시장 수요가 증가하고 있습니다. GLP-1 수용체 작용제는 인슐린 저항성, 심혈관 위험, 비만과 관련된 합병증을 가진 환자의 치료 전략의 핵심을 담당하고 있습니다.
당뇨병 유병률의 놀라운 증가는 GLP-1 유사체 시장의 주요 촉진제입니다. GLP-1 유사체는 기존 경구용 항당뇨병제 대비 우수한 HbA1c 강하 및 체중 감소 효과를 보이며, 주요 가이드라인에서 특정 환자군에서 2차 또는 1차 선택 약제로 권고되고 있습니다. 또한, 고위험군 환자에서 주요 심혈관계 부작용을 감소시키는 심혈관계 보호 효과도 있습니다. GLP-1 유사체의 임상적 가치에 대한 의사들의 인식이 높아지면서 처방이 크게 증가하고 있습니다. GLP-1 유사체는 당뇨병과 비만을 동시에 관리할 수 있기 때문에 당뇨병과 비만을 동시에 앓고 있는 환자에게 특히 유용합니다. GLP-1 유사체는 핵심 치료제로 자리매김하고 있으며, 개인 맞춤형 치료 및 결과 기반 치료로의 전환이 가속화되면서 시장 성장에 더욱 박차를 가하고 있습니다.
세계의 GLP-1 유사체 시장에 대해 조사했으며, 시장 개요와 함께 적응증별, 용도별, 용도별, 유통 채널별, 지역별 동향, 시장 진출 기업 프로파일 등의 정보를 전해드립니다.
Global GLP-1 analogues market is projected to witness a CAGR of 23.59% during the forecast period 2025-2032, growing from USD 41.63 billion in 2024 to USD 226.61 billion in 2032. The increasing reliance on GLP-1 receptor agonists for managing chronic metabolic conditions such as type 2 diabetes and obesity is bolstering the market's demand. These drugs are central to the therapeutic strategy for patients with insulin resistance, cardiovascular risk, and obesity-related complications.
The alarming rise in diabetes prevalence is a key driver of the GLP-1 analogues market. GLP-1 analogues, recommended by leading guidelines as a second-line or even first-line therapy in specific patient populations, offer superior HbA1c reduction and weight loss when compared to traditional oral antidiabetics. They also provide cardioprotective benefits, reducing major adverse cardiovascular events in high-risk patients. Growing awareness among physicians about the clinical value of GLP-1 analogues is resulting in a significant increase in prescriptions. Patients with both diabetes and obesity are particularly benefiting from these medications, as they help manage both conditions concurrently. The market's growth is further supported by the increasing shift toward personalized and outcomes-based treatments, in which GLP-1 analogues are considered cornerstone therapy.
Increasing Investments in Research Activities Boost Market Growth
Increasing investments in research activities are a key driver of growth in the global GLP-1 analogues market, which is projected to expand significantly in the coming years. These investments facilitate the development of innovative GLP-1 analogue drugs with enhanced efficacy, safety, and delivery methods, including oral formulations and combination therapies. Research efforts are also expanding the therapeutic applications of GLP-1 analogues beyond type 2 diabetes to include obesity, nonalcoholic steatohepatitis (NASH), Alzheimer's disease, and cardiovascular conditions. This broadening pipeline of indications attracts more patients and healthcare providers, fueling market demand. Additionally, ongoing clinical trials and patent-protected novel molecules from leading companies, such as Novo Nordisk A/S and Eli Lilly and Company, strengthen their market dominance and create high entry barriers for competitors. For instance, in August 2024, Eli Lilly and Company announced positive results from the SURMOUNT-1 Phase 3 trial showing that weekly injections of tirzepatide reduced the risk of developing type 2 diabetes by 94% in adults with pre-diabetes and obesity or overweight. Tirzepatide's dual action on GIP and GLP-1 receptors helps regulate appetite and insulin secretion, contributing to sustained weight loss and improved metabolic health. The study also confirmed a favourable safety profile, with mostly mild to moderate gastrointestinal side effects. These findings highlight tirzepatide's potential as a long-term therapy to prevent type 2 diabetes in high-risk populations. The focus on personalised medicine and enhanced patient outcomes through research further accelerates the adoption of this approach worldwide.
Strategic Collaborations Support Market Expansion
Innovation in GLP-1 analogues is accelerating, with pharmaceutical companies investing heavily in next-generation molecules and delivery platforms. Key developments include oral formulations, once-monthly dosing schedules, and dual or triple agonists that target multiple incretin pathways for enhanced efficacy. Companies are also exploring fixed-dose combinations of SGLT2 inhibitors, basal insulin, and other antidiabetics to offer more comprehensive glycemic control through collaborations and partnerships. Strategic partnerships and licensing agreements are reshaping the competitive landscape. Leading market players are teaming up with biotech companies to co-develop and commercialize promising candidates. For instance, in January 2024, Novo Nordisk A/S collaborated with two biotech companies, Cellarity Inc. and Omega Therapeutics, Inc., to develop new treatments for patients with obesity, cardiometabolic disorders, and liver diseases. This trend is also facilitating faster market entry into emerging economies through local manufacturing and distribution agreements.
Obesity Witnesses Rapid Market Growth
The ability of GLP-1 receptor agonists to promote weight loss has led to a significant paradigm shift in obesity pharmacotherapy. Increasing recognition of obesity as a disease requiring medical treatment, rather than solely lifestyle changes, is transforming the therapeutic landscape. Due to the rising incidences of obesity, the market is witnessing a significant increase in demand. As per the estimates of the Centres for Disease Control and Prevention, more than 2 in 5 adults in the United States have obesity. Governments, employers, and payers are acknowledging the long-term economic burden of untreated obesity, leading to broader reimbursement coverage in some regions. As public health policies begin to include funding for anti-obesity drugs, demand for GLP-1 analogues is expected to increase. Additionally, the launch of long-acting and oral variants has improved accessibility, particularly for patients averse to frequent injections, providing lucrative growth opportunities for the market.
North America Holds a Major Market Share
North America currently dominates the global GLP-1 analogues market, supported by a high prevalence of diabetes and obesity, favourable reimbursement policies, and strong healthcare infrastructure. As per the estimates of the government of Canada, approximately 9.6% of the country's population is diagnosed with diabetes. The presence of major manufacturers and the rapid adoption of new therapies have solidified the region's position. Direct-to-consumer advertising and increasing physician awareness also contribute to high prescription volumes.
Meanwhile, Asia-Pacific is expected to grow at the fastest pace over the forecast period. This growth is driven by rising urbanization, sedentary lifestyles, and dietary changes that have led to increased rates of metabolic disorders. Government initiatives for universal health coverage and access to diabetes treatment in countries such as India, China, and Indonesia are expanding the patient base. As local regulators fast-track approvals and multinational companies enter into licensing agreements, the market is witnessing significant growth opportunities in the region.
Impact of the U.S. Tariff on Global GLP-1 Analogues Market
The recent wave of U.S. tariffs on pharmaceuticals, including GLP-1 analogues such as Ozempic and Wegovy, is significantly disrupting the global market. These tariffs on imported active pharmaceutical ingredients (APIs) from countries such as Denmark, Ireland, China, and India are driving up production costs. While brand companies may temporarily absorb extra costs, generics and smaller API manufacturers, which operate on thin margins, are most vulnerable. This may lead to price hikes, supply shortages, and even some vendors exiting the market in the United States. Insurance premiums could also rise in the country and underinsured patients may lose access to these vital therapies.
Key Players Landscape and Outlook
The key players in the market are focusing on expanding their geographical presence to improve their market positioning. For instance, in March 2025, Eli Lilly and Company launched its obesity management drug, Mounjaro, in India. The injection is administered once a week and targets both GIP and GLP-1 receptors, offering significant weight loss and blood sugar control. Currently, the company aims to expand access to the drug without forming local partnerships. Its affordability and flexible dosing make it competitive against existing drugs including semaglutide, accelerating market penetration in India, which has millions affected by metabolic diseases. This strategic launch supports global market growth by increasing adoption in emerging markets and setting new standards for GLP-1 therapies worldwide.
All segments will be provided for all regions and countries covered
Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.